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As the use of left ventricular assist devices (LVAD) continues to burgeon, infectious complications remain a vital concern. Several investigators have reported their experiences with infections and LVAD support, noting that treatment of an established infection is both difficult and expensive. 1-4 Risk factors for infection include extended duration of LVAD support, prolonged
intensive care unit stay with invasive monitoring, poor preoperative nutritional status, and hemodialysis. [2] [3] [4] Among infectious complications, fungemia represents a serious concern due to the high association with adverse events including death. [5] [6] [7] The ability of fungal pathogens, especially Candida species, to adhere to foreign surfaces is well established, making fungemia in the setting of a large prosthetic device particularly problematic in terms of management and treatment. 8 Candidemia has been reported in 1.3-9 .7% of ventricular assist device recipients. 5 In 1995, universal, short-term fluconazole prophylaxis was recommended based on limited early data suggesting a high incidence of fungal infections during LVAD support. 7 This practice has continued at many centers, including ours. We sought to further characterize the epidemiology of fungemias during LVAD support by reviewing our experience from 1996 to 2009. 
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